Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights. To view the full press release, visit https://nnw.fm/taUAe About Beam Therapeutics Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines

Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.